Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term antibody persistence after infant/toddler Vaxelis or Infanrix hexa vaccination
2016-000274-37Phase 3Completed
- Sponsor
- MCM Vaccine
- Start
- Feb 2016
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of DTaP-IPV-Hep B-PRP-T vaccine and pertussis filamentous haemagglutinin in hepatitis B (HBV), pertussis, poliomyelitis and 3 more (2 arms), sponsored by MCM Vaccine. Primary endpoint: Percentage of subjects with anti-HBs concentration >=10 mIU/mL. Started Feb 2016; status: completed.
02
Drugs
DTaP-IPV-Hep B-PRP-T vaccinepertussis filamentous haemagglutinin
03
Conditions
hepatitis B (HBV)pertussispoliomyelitisHaemophilus influenzae type b disease (Hib)diphtheria
Beyond the preview
Go deeper on 2016-000274-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000274-37.